The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JULY 23, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Roche’s Chief Medical Officer and Head of Global Product Development.

Treatment 52

Treatment Virus Clinical Trials Government 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. Ricks , Lilly chairman and CEO.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

APRIL 6, 2021

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD). “We remain confident in baricitinib and believe it has the potential to be an effective new treatment option for these patients.”

Treatment 52

Treatment Clinical Trials Drugs Therapies 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 There was a 1.08 placebo; p=0.024).

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JULY 12, 2021

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. This press release features multimedia. View the full release here: [link]. “It About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households. About Ridgeback Biotherapeutics.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Codon

JANUARY 21, 2024

yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Scientists studied black men infected with syphilis for several decades while withholding known treatments. How are disease targets selected for challenge trials?

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Lilly subsequently developed bamlanivimab and etesevimab for administration together, in order to meet the potential challenge of SARS-CoV-2 variants likely to resist treatment with either monoclonal antibody used alone.

Government 52

Government Long-Term Care Facilities Hospitals Treatment 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Production 52

The Pharma Data

APRIL 15, 2022

The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor’s offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage. In the study, the test was shown to have 91.2% The study also showed that, in a population with only 4.2%

FDA 52

FDA Licensing Licensing Production 52

The Pharma Data

MARCH 22, 2021

The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S. 1 COVID-19-related hospitalization or death through day 29. Key results from phase III REGN-COV 2067 trial in non-hospitalised patients 1-3.

Virus 52

Virus Clinical Trials Trials FDA 52

Codon

MAY 11, 2023

It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. In one instance, “a user heard the words ‘I don’t have my driver’s license yet.’ Read more in WIRED. The vaccine was 82.6 People 2,000 years ago == people today.

Vaccine 52

Vaccine Engineering Licensing Licensing 52

Codon

MAY 11, 2023

It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. In one instance, “a user heard the words ‘I don’t have my driver’s license yet.’ Read more in WIRED. The vaccine was 82.6 People 2,000 years ago == people today.

Vaccine 52

Vaccine Engineering Licensing Licensing 52

The Pharma Data

OCTOBER 29, 2020

Interim analyses were conducted after patients completed 12 and 36 weeks of treatment, the latter for the primary endpoint of the Phase 2 part of the study. ” In March, the FDA granted Breakthrough Therapy designation to baricitinib for the treatment of AA based on positive Phase 2 results from BRAVE-AA1.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. Non-GAAP EPS of $1.74 for the third quarter of 2020 excludes acquisition- and divestiture-related costs, restructuring costs, pretax charges of $1.1 Year-to-date results can be found in the attached tables. COVID-19 Research Highlights.

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

JANUARY 26, 2021

While the preliminary nature of Phase 2 results from COVID-19 neutralizing monoclonal antibodies may have limited acceptance of treatment, these Phase 3 data further strengthen the available evidence,” said Daniel Skovronsky, M.D., INDIANAPOLIS, Jan. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

NOVEMBER 20, 2020

Food and Drug Administration (FDA) has approved Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). . Eiger licensed exclusive worldwide rights to lonafarnib from Merck, known as MSD outside of the United States and Canada.

FDA Approval 52

FDA Approval FDA Clinical Trials Disease 52

The Pharma Data

NOVEMBER 5, 2020

. “Last week, Regeneron achieved an important milestone in the fight against COVID-19 with prospective Phase 2/3 results showing REGN-COV2 significantly reduced virus levels and the need for further medical attention in non-hospitalized patients; we have shared these important data with regulatory authorities,” said Leonard S.

Production 52

Production FDA FDA Approval Trials 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 118

Therapies Virus DNA Clinical Trials 118

The Pharma Data

NOVEMBER 29, 2020

3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. It also can cause more serious conditions like hepatitis and pneumonia, which often require hospitalization, as well as increase the likelihood of transplant rejection and graft-versus-host disease. 1 Gilbert C and Boivin G.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

Codon

FEBRUARY 27, 2024

The man was in Hong Kong for kidney treatment. Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. While the consensus that emerged among experts was that the virus spread primarily via airborne transmission , it also made use of another route: fomite transmission. Always free.

Virus 69

Virus Hospitals Production Regulations 69

Drug Discovery World

SEPTEMBER 16, 2022

According to the Cell and Gene Therapy Catapult, the campus acts as a “vital focal point for companies looking to develop and commercialise advanced therapy treatments, as well as attracting significant investment from pharmaceutical companies and venture capitals firms.” . billion in funding. .

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Ricks, Lilly’s chairman and CEO.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

NOVEMBER 20, 2020

Casirivimab and imdevimab are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19. . “The Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

Agency IQ

NOVEMBER 3, 2023

Because they focus on treatment of a specific condition, synthetic biotics must be studied under an investigational new drug application (IND). Highly engineered microbes that are targeted to the treatment or diagnosis of a specific condition must pursue a BLA to be marketed for that specific purpose. What’s next?

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

NOVEMBER 21, 2020

21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. ” “REGEN-COV2 is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D.

FDA 40

FDA Clinical Trials Hospitals Government 40

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. The pessimism of just a few years before was replaced with exuberant optimism.

Engineering 125

Engineering Virus DNA Therapies 125

The Pharma Data

SEPTEMBER 7, 2021

We are also participating in partnerships and research efforts to advance diagnostics and treatments for COVID-19 and supporting relief efforts across the globe. Bristol Myers Squibb is conducting real world data research to further advance potential treatment approaches of significant cardiovascular complications of COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

OCTOBER 18, 2020

Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study.

Immune Response 40

Immune Response Hospitals Virus Treatment 40

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. The product is designed for the prevention and treatment of COVID-19, along with related coronaviruses. Kate Krav-Rude/Shutterstock.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52